Celecoxib/lisinopril - Marina Biotech

Drug Profile

Celecoxib/lisinopril - Marina Biotech

Alternative Names: IT 102

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IthenaPharma
  • Developer Marina Biotech
  • Class Analgesics; Antihypertensives; Antineoplastics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
  • Mechanism of Action ACE inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Inflammation
  • Preclinical Arthritis; Cancer; Hypertension; Pain

Most Recent Events

  • 08 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 42nd European Society for Medical Oncology (ESMO-2017)
  • 07 Apr 2017 Marina Biotech plans a bioequivalence study in Healthy volunteers (Marina Biotech, Form 10 K, March 2017)
  • 03 Apr 2017 Marina Biotech enters into a definitive agreement with Windlas Healthcare to manufacture celecoxib/lisinopril
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top